

LIST OF TABLES

CLASSIFICATION OF LIPOSOMES

Table. 2.1	a) Based on structural parameters (size and number of bilayers)	18
	b) Based on method of liposome preparation	
Table 2.2	Liposome-based products developed or under development	34
Table 2.3	Summary of HPLC methods for analysis of cyclosporine	81
Table 2.4	Summary of HPLC methods for analysis of leuprolide acetate	100
Table 3.1	Calibration curve for estimation of phosphatidyl choline	122
Table 3.2	Optical characteristics for ammonium ferrothiocyanate-phosphatidyl choline complex in chloroform	123
Table 3.3	Calibration curve for estimation of cholesterol	126
Table 3.4	Optical characteristics for ammonium ferrothiocyanate-phosphatidyl choline complex in chloroform	127
Table 3.5	Calibration curve for cyclosporine in Tetrahydrofuran /methanol (1:1)	129
Table 3.6	Optical characteristics for cyclosporine in Tetrahydrofuran /methanol (1:1)	129
Table 3.7	Calibration curve for leuprolide acetate in 0.1N NaOH	132
Table 3.8	Optical characteristics for leuprolide acetate in 0.1N NaOH	133
Table 3.9	Calibration curve for DNA in Tris buffer	136
Table 3.10	Optical characteristics for DNA in Tris buffer	136
Table 3.11	Calibration curve for leuprolide acetate in PBS	139
Table 3.12	Optical characteristics for leuprolide acetate in PBS	139
Table 3.13	Calibration curve for DNA in PBS	142
Table 3.14	Optical characteristics for DNA in PBS	142
Table 3.15	Calibration curve for mPEG5000-CC-PE	145
Table 3.16	Optical characteristics for mPEG5000-CC-PE	145
Table 3.17	Calibration curve for mPEG2000-CC-PE	146
Table 3.18	Optical characteristics for mPEG2000-CC-PE	147
Table 4.1	Effect of process variables for the preparation of charged liposomes containing cyclosporine	170

Table 4.2	Optimisation of parameters for preparation of liposomes containing cyclosporine	171
Table 4.3	Coded values of the formulation parameters of cyclosporine loaded liposomes by 3^3 factorial design	172
Table 4.4	3^3 Factorial design layout of cyclosporine loaded liposomes	173
Table 4.5	Model coefficients estimated by multiple linear regression for cyclosporine loaded liposomes by 3^3 factorial design	174
Table 4.6	Analysis of variance (ANOVA) of full and reduced models of cyclosporine loaded liposomes by 3^3 factorial design	174
Table 4.7	Effect of positive charge on encapsulation efficiency of cyclosporine loaded liposomes	175
Table 4.8	Effect of negative charge on encapsulation efficiency of cyclosporine loaded liposomes	175
Table 4.9	Entrapment efficiency of optimized batches of freshly prepared liposomal suspensions containing cyclosporine.	176
Table 4.10	Coded values of the formulation parameters of conventional (LL) leuprolide acetate liposomes by 3^3 factorial design	181
Table 4.11	3^3 Full factorial design of conventional (LL) leuprolide acetate liposomes	182
Table 4.12	Model coefficients estimated by multiple linear regression of leuprolide acetate loaded liposomes by 3^3 factorial design	183
Table 4.13	Analysis of variance (ANOVA) of full and reduced models of leuprolide acetate loaded liposomes by 3^3 factorial design	183
Table 4.14	Test data set for validating ANN and MLR model of leuprolide acetate loaded liposomes by 3^3 factorial design	185
Table 4.15	Entrapment efficiency of optimized batches freshly prepared liposomal suspension.	186
Table 4.16	Optimisation of parameters for the preparation of conventional liposomes containing DNA	189
Table 4.17	Results of electrolyte induced flocculation test on conventional liposomes containing Leuprolide acetate	191
Table 4.18	Results of electrolyte induced flocculation test on plain liposomes containing DNA	182

Table 4.19	Optimization of mPEG-5000-CC-PE concentration, required for steric stabilization of Leuprolide acetate containing liposomes, using electrolyte induced flocculation test	213
Table 4.20	Optimization of mPEG-2000-CC-PE concentration, required for steric stabilization of leuprolide acetate containing liposomes, using electrolyte induced flocculation test	214
Table 4.21	Optimization of mPEG5000-CC-PE concentration, required for steric stabilization of DNA containing liposomes, using electrolyte induced flocculation test	216
Table 4.22	Optimization of mPEG2000-CC-PE concentration, required for steric stabilization of DNA containing liposomes, using electrolyte induced flocculation test	217
Table 4.23	Optimization of mPEG2000-CC-PE concentration, required for steric stabilization of DNA containing liposomes, using electrolyte induced flocculation test	218
Table 4.24	Entrapment efficiency of optimized batches of freshly prepared liposomal suspension of DNA containing liposomes. Each value is the mean of triplicate results	219
Table 5.1	Attributes of plain and sterically stabilized liposomes containing CsA, Leuprolide acetate and DNA	242
Table 5.2	Analysis of variance (ANOVA) table for drug entrapment in conventional and charged liposomes containing cyclosporine	243
Table 5.3	Analysis of variance (ANOVA) table for drug entrapment in conventional and sterically stabilized liposomes containing leuprolide acetate	243
Table 5.4	Analysis of variance (ANOVA) table for drug entrapment in conventional and sterically stabilized liposomes containing DNA	243
Table 6.1	<i>In vitro</i> drug release studies of neutral liposomes containing cyclosporine	268
Table 6.2	<i>In vitro</i> drug release studies of positive charged liposomes containing cyclosporine	268
Table 6.3	<i>In vitro</i> drug release studies of negative charged liposomes containing cyclosporine	269
Table 6.4	<i>In vitro</i> drug release studies of conventional liposomes containing leuprolide acetate	269

Table 6.5	<i>In vitro</i> drug release studies of sterically stabilized liposomes (mPEG-5000-CCPE) containing leuprolide acetate	270
Table 6.6	<i>In vitro</i> drug release studies of sterically stabilized liposomes (mPEG-2000-CCPE) containing leuprolide acetate	270
Table 6.7	<i>In vitro</i> drug release studies of conventional liposomes containing DNA	271
Table 6.8	<i>In vitro</i> drug release studies of sterically stabilized liposomes (mPEG5000-CCPE) containing DNA	271
Table 6.9	<i>In vitro</i> drug release studies of sterically stabilized liposomes (mPEG2000-CCPE) containing DNA	272
Table 6.10	<i>In vitro</i> drug release studies of cationic sterically stabilized liposomes (mPEG2000) containing DNA	272
Table 6.11	Parameters of release kinetics for conventional and sterically stabilized liposomes containing cyclosporine, leuprolide acetate and DNA	273
Table 7.1	Particle size determination of the cyclosporine loaded liposomal dispersions after storing at different temperatures for a period of 30 days	293
Table 7.2	% Entrapment Efficiency of the liposomal dispersion before lyophilisation after storage of 7 days, 15 days and 1 month at various temperatures	293
Table 7.3	Percentage drug retention of the rehydrated lyophilized liposomal formulations after storing at different temperatures for a period of 6 months	294
Table 7.4	Particle size determination of the lyophilized liposomal formulations after storing at different temperatures for a period of 6 months	295
Table 7.5	Particle size determination of the leuprolide acetate loaded liposomal dispersions after storing at different temperatures for a period of 30 days	296
Table 7.6	% Entrapment Efficiency after storage of 7 days, 15 days and 1 month at various temperatures	296
Table 7.7	Steric stability studies of leuprolide acetate loaded liposomal dispersions after storing at different temperatures for a period of 30 days	297

Table 7.8	Percentage drug retention of the rehydrated lyophilized leuprolide acetate loaded liposomal formulations after storing at different temperatures for a period of 6 months	298
Table 7.9	Percentage entrapment efficiency of the rehydrated lyophilized DNA loaded liposomal formulations after storing at different temperatures for a period of 6 months	298
Table 7.10	Steric stability studies of rehydrated lyophilized DNA loaded liposomal formulations after storing at different temperatures for a period of 6 months	299
Table 7.11	% drug retention of the DNA loaded liposomal suspension after rehydration and storage at 7 days and 15 days at various temperatures	300
Table 7.12	Particle size determination of the DNA loaded liposomal dispersions after rehydration and storing at different temperatures for a period of 15 days	300
Table 7.13	Steric stability studies of the DNA loaded liposomal dispersions after rehydration and storing at different temperatures for a period of 15 days	301
Table 8.1	Concentration dependent apoptosis of cyclosporine on mouse splenocytes	315
Table 8.2	Induction of apoptosis in Splenic lymphocytes at 24 h after incubation with CsA and its liposomal preparation studied by the flow cytometric analysis of DNA content, expressed as the percentage of the number of apoptotic cells	317
Table 8.3	Percentage of CD4+ cells and CD8+ cells in the spleen treated with 1.0 μ M of CsA and liposomal CsA	318
Table 9.1	<i>In vitro</i> cytotoxicity study of leuprolide acetate and its liposomes	327
Table 10.1	Effect of pH on radiolabeling efficiency of cyclosporine and its liposomal formulations	339
Table 10.2	Effect of incubation time on radiolabeling efficiency of cyclosporine and its liposomal formulations	340
Table 10.3	Effect of SnCl ₂ .2H ₂ O concentration on radiolabeling efficiency of cyclosporine and its liposomal formulations	341
Table 10.4	Stability studies of radiolabeled cyclosporine and its liposomal formulations in saline	342

Table 10.5	Stability studies of radiolabeled cyclosporine and its liposomal formulations in serum	342
Table 10.6	DTPA challenging test of cyclosporine and its liposomal formulations	343
Table 10.7	Effect of pH on radiolabeling efficiency of leuprolide acetate and its liposomal formulations	345
Table 10.8	Effect of incubation time on radiolabeling efficiency of leuprolide acetate and its liposomal formulations	346
Table 10.9	Effect of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ concentration on radiolabeling efficiency of leuprolide and its liposomal formulations	347
Table 10.10	Stability studies of radiolabeled leuprolide and its liposomal formulations in saline	348
Table 10.11	Stability studies of radiolabeled leuprolide and its liposomal formulations in serum	348
Table 10.12	DTPA challenging test of leuprolide and its liposomal formulations	349
Table 10.13	Effect of pH on radiolabeling efficiency of DNA and its liposomal formulations	351
Table 10.14	Effect of incubation time on radiolabeling efficiency of DNA and its liposomal formulations	352
Table 10.15	Effect of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ concentration on radiolabeling efficiency of DNA and its liposomal formulations	353
Table 10.16	Stability studies of radiolabeled DNA and its liposomal formulations in saline	354
Table 10.17	Stability studies of radiolabeled DNA and its liposomal formulations in serum	354
Table 10.18	DTPA challenging test of DNA and its liposomal formulations	355
Table 11.1	Results of the blood kinetic data of cyclosporine (CsA)	366
Table 11.2	Results of the blood kinetic data of positive charged liposomes containing cyclosporine (CPL)	366
Table 11.3	Results of the blood kinetic data of negative charged liposomes containing cyclosporine (CNL)	367
Table 11.4	Results of the blood kinetic data of neutral liposomes containing cyclosporine (CL)	367
Table 11.5	Results of the blood kinetic data of Leuprolide acetate (leuprolide)	369
Table 11.6	Results of the blood kinetic data of conventional liposomes containing leuprolide (LL)	369

Table 11.7	Results of the blood kinetic data of sterically stabilized liposomes containing leuprolide (SLL 5000)	370
Table 11.8	Results of the blood kinetic data of sterically stabilized liposomes containing leuprolide (SLL2000)	370
Table 11.9	Results of the blood kinetic data of DNA	372
Table 11.10	Results of the blood kinetic data of conventional liposomes containing DNA (DL)	372
Table 11.11	Results of the blood kinetic data of sterically stabilized liposomes containing DNA (SDL5000)	373
Table 11.12	Results of the blood kinetic data of sterically stabilized liposomes containing DNA (SDL2000)	373
Table 11.13	Results of the blood kinetic data of cationic sterically stabilized liposomes containing DNA (CSDL2000)	374
Table 11.14	Pharmacokinetic parameters for the in vivo studies of conventional and sterically stabilized liposomes containing cyclosporine, leuprolide acetate and DNA in rabbit	375
Table 11.15	Biodistribution of CsA in mice	376
Table 11.16	Biodistribution of CsA in mice	376
Table 11.17	Biodistribution of CPL in mice	377
Table 11.18	Biodistribution of CPL in mice	377
Table 11.19	Biodistribution of CNL in mice	378
Table 11.20	Biodistribution of CNL in mice	378
Table 11.21	Biodistribution of CL in mice	379
Table 11.22	Biodistribution of CL in mice	379
Table 11.23	Biodistribution of leuprolide acetate in EAT tumor bearing mice	381
Table 11.24	Biodistribution of leuprolide acetate in EAT tumor bearing mice	381
Table 11.25	Biodistribution of LL in EAT tumor bearing mice	382
Table 11.26	Biodistribution of LL in EAT tumor bearing mice	382
Table 11.27	Biodistribution of SLL5000 in EAT tumor bearing mice	383
Table 11.28	Biodistribution of SLL5000 in EAT tumor bearing mice	383
Table 11.29	Biodistribution of SLL2000 in EAT tumor bearing mice	384
Table 11.30	Biodistribution of SLL2000 in EAT tumor bearing mice	384
Table 11.31	Biodistribution of DNA in mice	387

Table 11.32	Biodistribution of DNA in mice	387
Table 11.33	Biodistribution of DL in mice	388
Table 11.34	Biodistribution of DL in mice	388
Table 11.35	Biodistribution of SDL5000 in mice	389
Table 11.36	Biodistribution of SDL5000 in mice	389
Table 11.37	Biodistribution of SDL2000 in mice	390
Table 11.38	Biodistribution of SDL2000 in mice	390
Table 11.39	Biodistribution of CSDL2000 in mice	391
Table 11.40	Biodistribution of CSDL2000 in mice	391
Table 11.41	Pharmacokinetic parameters for the <i>in vivo</i> studies of conventional and sterically stabilized liposomes containing cyclosporine, leuprolide acetate and DNA in mice	393
Table 11.42	<i>In vitro</i> testing for drug retention within liposomes containing cyclosporine in human plasma	394
Table 11.43	<i>In vitro</i> testing for drug retention within liposomes containing leuprolide acetate in human plasma	394
Table 11.44	<i>In vitro</i> testing for drug retention within liposomes containing DNA in human plasma	394
Table 12.1	Nephrotoxicity study of Cyclosporine and its liposomes on the serum levels of creatinine, urea, uric acid and BUN	420